Find the latest updates on COVID-19 treatments

A Cleveland Clinic enterprise team is working on strategies for the equitable distribution and delivery of COVID-19 treatments. Please see below for current treatments as well as Emergency Use Authorizations (EUA) and U.S. Food and Drug Administration (FDA) approval status for anti-viral and preventative therapies.

Monoclonal antibody infusions for treatment of mild to moderate COVID-19

Cleveland Clinic provides monoclonal antibody infusions to treat mild to moderate COVID-19 infection in certain patients who have a high risk for severe illness.

In Northeast Ohio, we offer outpatient COVID-19 monoclonal antibody infusions at three locations:

  • Marymount Hospital, adults
  • Akron General Health and Wellness Center located at Green, the preferred location for adults with immunocompromising disorders and therapies
  • Main campus R building, pediatrics

In Florida, we offer outpatient COVID-19 monoclonal antibody infusions at the following locations:

  • Outpatient infusion sites: Martin North, Weston
  • ED infusion sites: Martin North, Martin South, Tradition Hospital, St. Lucie West, Weston, Indian River

Currently, the demand for COVID-19 monoclonal antibody infusions outweighs the supply of infusion appointments. There are additional locations throughout Ohio and Florida, outside of Cleveland Clinic, which offer COVID-19 monoclonal antibody infusions.

New long-acting monoclonal antibodies for pre-exposure prevention of COVID-19

Earlier this month, the FDA issued an EUA for AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together) for the prevention of COVID-19 in certain adults and pediatric individuals 12 years of age and older weighing at least 88 pounds.

It is a COVID-19 monoclonal antibody combination for prevention of COVID-19 infection in two patient populations:

  1. Patients who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination
  2. Patients for whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).

The product is only authorized for those individuals meeting one of the two criteria above, who are not currently infected with COVID-19 and who have not recently been exposed to an individual infected with COVID-19 who meet the above criteria.

This therapy is provided by the federal government on allocation and has not yet been released to the state health departments for distribution. When product is available, distribution will be limited and allocation information will be shared.

Molnupiravir FDA approval status

Molnupiravir is an oral antiviral for treatment of mild to moderate COVID-19 infection in the outpatient setting. It is currently under review by the FDA and is not available in the U.S.

If it is approved, this product will be purchased by the federal government and distributed by state health departments on limited allocation.

We will provide updates as additional information and approvals when available.

For the latest information on COVID-19 monoclonal antibody therapeutics, click here.